The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic

Status Completed

Clinical Trial Summary

Endoscopic submucosal dissection (ESD) is an effective treatment for early gastric cancer or premalignant lesions in the stomach. ESD enables en bloc resection of gastrointestinal neoplasms, increases the rates of histologically complete resections, and also reduces local recurrence rates. Despite these advantages, ESD is thought to induce various complications. Wellknown ESD-related complications include perforation, postoperative bleeding, or stricture. In addition, minor adverse events after ESD are also commonly noticed. Pain is one of these frequently noticed minor ESD related complications, is the main reason for prolongation of the hospital stay, and is related to patients' compliance; however, there is a tendency to neglect or underestimate post-ESD pain. The causes of pain associated with ESD are thought to be associated with transmural burn or transmural air leak. Some studies have tried to control localized pain during and after ESD using local lidocaine, single dose postoperative intravenous dexamethasone or a transdermal fentanyl patch. Magnesium has been reported to alter the perception and duration of pain and produce important analgesic effects. It is included the suppression of neuropathic pain, potentiation of morphine analgesia, and attenuation of morphine tolerance. Although the exact mechanism is not yet fully understood, the analgesic properties of magnesium are believed to stem from regulation of calcium influx into the cell and antagonism of N-methyl-D-aspartate receptors in the central nervous system. Also, magnesium may prolong neuromuscular blockade after administration of neuromuscular blocking drugs, increase sedation and contribute to serious cardiac morbidity. And magnesium as a hypotensive anaesthesia technique supply objectively better operative field, reduction in the duration of surgery and reduced blood loss. There have been no previous trials on the use of magnesium specifically for pain control following ESD. Thus, the purpose of this study was to assess the efficacy of intravenous magnesium for pain relief after ESD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02235246
Study type	Interventional
Source	Yonsei University
Contact
Status	Completed
Phase	Phase 4
Start date	October 2014
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02543411` - Use of Lidocaine in Endoscopic Submucosal Dissection	N/A
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Active, not recruiting	`NCT00506207` - A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy	Phase 1
Completed	`NCT04830618` - Aberrant DNA Methylation to Predict Metachronous Gastric Neoplasms
Completed	`NCT00252161` - A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer	Phase 3
Recruiting	`NCT04622098` - Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt
Terminated	`NCT01870791` - Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer	Phase 2
Completed	`NCT03255070` - A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)	Phase 1
Recruiting	`NCT06342427` - Stomach Cancer Exosome-based Detection
Recruiting	`NCT04780256` - Endoscopic Resection of Gastrointestinal Neoplasms
Recruiting	`NCT03065257` - Endoscopic Resection Multicenter Registry	N/A
Recruiting	`NCT05804331` - The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Completed	`NCT05265221` - Learning Curve for Gastric Endoscopic Submucosal Dissection
Recruiting	`NCT03597581` - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer	Phase 1
Completed	`NCT00112099` - GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110	Phase 3
Recruiting	`NCT04466631` - Health and Employment After Gastro Intestinal Surgery - HEAGIS2
Terminated	`NCT00149266` - Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)	Phase 3
Completed	`NCT00149279` - A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer	Phase 3
Recruiting	`NCT06362070` - Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy	N/A
Completed	`NCT01824953` - Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms